Ipriflavone (7-IPF) from Soy

Clinical Studies
References


Also called: 7-Isopropoxy-Isoflavone, or 7-IPF.

Ipriflavone is an isoflavone manufactured from daidzein, a compound derived from soy. Ipriflavone may inhibit bone resorption and prevent bone density loss without suppressing the rate of bone formation. Ipriflavone has no direct estrogenic activity, but might potentiate the effects of estrogen on bone. Ipriflavone is used for osteoporosis, preventing drug-induced osteoporosis, relieving osteoporotic pain, and for reducing bone loss in hemiplegic stroke patients.

Published Clinical Studiescl top
Ipriflavone (7-IPF) from Soy

  • The effect of oral ipriflavone on the rat mandible during growth.
  • Effects of Siberian ginseng extract and ipriflavone on the development of glucocorticoid-induced osteoporosis.
  • The synthetic phytoestrogen, ipriflavone, and estrogen prevent bone loss by different mechanisms.

The effect of oral ipriflavone on the rat mandible during growth.1

Maki K, Nishida I, Kimura M.

 

Department of Pediatric Dentistry, Kyushu Dental College, kitakyushu City, Japan.

Different types of ipriflavone (IF) have been reported to be effective when used as a remedy for bone loss due to osteoporosis. However, no information is available regarding the relationship between IF and jaw bone structure. The aim of this study was to examine the effect of IF on rat mandibles during the growth stage. Thirty-two 5-week-old Wistar male rats were divided into four groups. The control group was fed a standard diet, group A received a low calcium diet (calcium content 30 per cent of the standard diet) for 6 weeks, and the other two groups were fed a low calcium diet for 3 weeks and then a standard diet without IF (group B) or with IF (group C) for 3 weeks. In addition, distilled water was provided for all groups. The effects of IF on mandibular size and bone mineral content were investigated, using lateral cephalometric analysis and peripheral quantitative computed tomography (pQCT).For mandibular length, the control group showed a significantly higher value than groups A and B (P < 0.01, P < 0.05, respectively), while group C demonstrated a significantly higher value than group A (P < 0.01). In addition, the control group and group C showed significantly higher values for mandibular ramus height than group A (P < 0.01). However, bone mineral density in trabecular bone was significantly higher in the control group than in the other groups (P < 0.01) and bone mineral density in cortical bone was significantly higher in the control group than groups A, B and C (P < 0.01, P < 0.01, P < 0.05, respectively). Bone mineral density in both trabecular and cortical bone was significantly higher in group C than in groups A and B (P < 0.01, P < 0.05, respectively). These results indicate that complete recovery from calcium deficiency to the level of the control group may not be attainable, even though IF enhances calcium absorption to act on bone cells and promote bone construction. The importance of calcium intake in the early stages of development was confirmed. These findings also suggest an effect of IF on jaw bone structure.

PMID: 15743860 [PubMed - in process]

back

2
Effects of Siberian ginseng extract and ipriflavone on the development of glucocorticoid-induced osteoporosis.

Kropotov AV, Kolodnyak OL, Koldaev VM.

 

Department of Pharmacology, Vladivostok State Medical University.

Siberian ginseng extract produced a protective effect during experimental steroid-induced osteoporosis, which was comparable with the influence of ipriflavone.

PMID: 12360344 [PubMed - indexed for MEDLINE]

back

3
The synthetic phytoestrogen, ipriflavone, and estrogen prevent bone loss by different mechanisms.

Arjmandi BH, Birnbaum RS, Juma S, Barengolts E, Kukreja SC.

 

Department of Nutritional Sciences, 416 Human Environmental Sciences, Oklahoma State University, Stillwater, Oklahoma 74078, USA.

Ipriflavone (IP), a synthetic isoflavone has been reported to prevent bone loss in both postmenopausal women and ovariectomized (ovx) rats. The purpose of this study was to compare and contrast some of the bone protective mechanisms of IP to those of 17beta-estradiol (E(2)) in ovarian hormone deficiency. Forty-eight 95-day-old Sprague-Dawley rats were assigned to four groups: sham, ovx, ovx+IP, and ovx+E(2). The doses of IP and E(2) were 100 mg and 10 microg/kg body weight per day, respectively. Rats were fed a diet that contained 0.4% calcium, 0.3% phosphorus, and 0.195 nmol vitamin D(3)/g diet. After sacrifice, left femoral bone densities were measured and bone histomorphometry was performed on the proximal tibial metaphysis. Ipriflavone as well as E(2) treatment completely prevented the ovx-induced femoral bone density loss. However, in contrast to E(2), IP did not lower the ovx-induced rise in serum alkaline phosphatase (ALP) activity or insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 concentrations. On histomorphometry analysis, the ovariectomy-induced increase (P < 0. 09) in bone formation rate (BFR) was significantly (P < 0.05) suppressed by E(2) treatment, whereas this higher BFR was maintained in IP-treated animals. These findings indicate that IP is effective in preventing the ovx-associated bone loss. The bone protective mechanisms of IP in ovarian hormone deficiency may be different from those of E(2) and may involve increased rates of bone formation.

PMID: 10602847 [PubMed - indexed for MEDLINE]

back to top

Referencesre

  1. Arjmandi BH, Birnbaum RS, Juma S, et al. The synthetic phytoestrogen, ipriflavone, and estrogen prevent bone loss by different mechanisms. Calcif Tissue Int 2000;66(1):61-5.
  2. Melis GB, Paoletti AM, Bartolini R, et al. Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium. Bone Miner 1992;19,Suppl 1:S49-56.
  3. Agnusdei D, Adami S, Cervetti R, et al. Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis. Bone Miner 1992;19,Suppl 1:S43-8.
  4. Sato Y, Kuno H, Kaji M, et al. Effect of ipriflavone on bone in elderly hemiplegic stroke patients with hypovitaminosis D. Am J Phys Med Rehabil 1999;78(5):457-63.
  5. Ohta H, Komukai S, Makita K, et al. Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass. Horm Res 1999;51:178-83.
  6. Head KA. Ipriflavone: an important bone-building isoflavone. Altern Med Rev 1999;4:10-22.
  7. Agnusdei D, Bufalino L. Efficacy of ipriflavone in established osteoporosis and long-term safety. Calcif Tissue Int 1997;61,Suppl 1:S23-7.
  8. Gennari C, Adami S, Agnusdei D, et al. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass. Calcif Tissue Int 1997;61,Suppl 1:S19-22.
  9. Petilli M, Fiorelli G, Benvenuti S, et al. Interactions between ipriflavone and the estrogen receptor. Calcif Tissue Int 1995;56(2):160-5.
  10. Alexandersen P, Toussaint A, Christiansen C, et al. Ipriflavone in the treatment of postmenopausal osteoporosis: A randomized comtrolled trial. JAMA 2001;285:1482-8.
  11. Gennari C, Agnusdei D, Crepaldi G, et al. Effect of ipriflavone-a synthetic derivative of natural isoflavones-on bone mass loss in the early years after menopause. Menopause 1998;5(1):9-15.
  12. Agnusdei D, Crepaldi G, Isaia G, et al. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss. Calcif Tissue Int 1997;61:142-7.
  13. Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women. Maturitas 1997;28(1):75-81.
  14. Agnusdei D, Gennari C, Bufalino L. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone. Osteoporos Int 1995;5(6):462-6.
  15. Valente M, Bufalino L, Castiglione GN, et al. Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass. Calcif Tissue Int 1994;54(5):377-80.
  16. Ushiroyama T, Okamura S, Ikeda A, et al. Efficacy of ipriflavone and 1 alpha vitamin D therapy for the cessation of vertebral bone loss. Int J Gynaecol Obstet 1995;48(3):283-8.
  17. Agnusdei D, Zacchei F, Bigazzi S, et al. Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis. Drugs Exp Clin Res 1989;15(2):97-104.
  18. Agnusdei D, Camporeale A, Gonnelli S, et al. Short-term treatment of Paget's disease of bone with ipriflavone. Bone Miner 1992;19 Suppl 1:S35-42.
  19. Hyodo T, Ono K, Koumi T, et al. A study of the effects of ipriflavone administration on hemodialysis patients with renal osteodystrophy: preliminary report. Nephron 1991;58:114-5.
  20. Monostory K, Vereczkey L, Levai F, et al. Ipriflavone as an inhibitor of human cytochrome P450 enzymes. Br J Pharmacol 1998;123(4):605-10.